INmune Bio Inc.
@INmuneBio
Followers
5K
Following
2K
Media
842
Statuses
2K
INmune Bio (Nasdaq: INMB) is developing therapies that harness patient’s immune system to treat disease. Our focus is on #cancer, #Alzheimer’s disease.
Boca Raton, FL
Joined October 2016
RT @CumulusNeuro: For #AlzheimersAwarenessMonth, @CumulusNeuro is honored to be sponsoring a webinar on Friday November 10th titled "Levera….
0
2
0
Another episode of INside INmune Bio is out! 🎥 Our CFO and host David Moss unravels the "master cytokine," tumor necrosis factor, with our CEO Dr. RJ Tesi. Watch the full episode here:
1
0
4
Our CFO David Moss has been featured in a recent @CBS News article discussing the groundbreaking developments in #Alzheimers research and #healthcare economics. Read the full article to learn more about Alzheimer's research and healthcare economics:
2
1
8
📢 We are pleased to announce our authorization of a Clinical Trial Application to initiate a Phase 2 trial in early Alzheimer’s disease with XPro™. Full release here: #Alzheimers #AlzheimersDisease #ADtreatment.
0
1
7
Our CEO Dr. RJ Tesi was featured in a recent @mnt article exploring a new blood-based biomarker test available for individuals to gauge their risk for developing Alzheimer’s. Read the full article here: . #Neurology #BrainHealth #AlzheimersDisease.
0
0
2
🎥 David Moss CFO sat down with Joshua Schoonover, General Counsel to discuss intellectual property and reference biologics exclusivity, and how these subjects relate to INmune Bio's clinical programs. Click here to watch:
0
0
1
🧬 INmune Bio hosted its first ever INside INmune Bio video series. This series is directed to get a peek behind the curtain of the inner workings of INmune Bio.
1
0
1
Our CFO David Moss was featured in an article by @KFF. David shares “A lot of clinicians are excited about the drug, and patients are hearing about it, it’s a money center for infusion centers and MRI operators.”. Click here to read more:
0
0
3
Our CEO Dr. RJ Tesi was featured by @MedicalNewsToday in an article that discusses the potential of p38 inhibitors being used to treat #Alzheimers. Read the full story to hear his thoughts on the recent research. #Neurology #BrainHealth #AD
0
0
3
Our CEO @RJ Tesi has been featured in a recent article from @VeryWell Health about recent evidence suggesting that elevated cholesterol levels could play a role in the progression and development of #Alzheimers. Click here to read more:
0
0
3
#ICYMI, our CEO RJ Tesi spoke with @NeurologyLive during #AAIC23 about INmune Bio's recently-announced MRI biomarker data. Read more here: #Neurology #BrainHealth #Alzheimers #Innovation.
0
0
2
Our CEO Dr. RJ Tesi has been featured in a recent @mnt article exploring the potential of CRISPR gene therapy in the treatment of #Alzheimers. Read the full article here: #INmuneBio #AlzheimersResearch #CRISPR #GeneTherapy #Neuroscience.
0
0
3
Our CEO Dr. RJ Tesi recently penned an article for Clinical Leader about why so many clinical trials for #Alzheimers have failed. Read his full piece here:
0
0
2
At last week's annual @Alzheimer's Association 2023 International Conference (#AAIC23), we were proud to announce new findings from data involving novel MRI biomarkers in participants from an open-label Phase 1b study. Read the full release here:
0
1
7
#ICYMI our CEO Dr. RJ Tesi delivered the opening keynote presentation at the 5th World Aging and Rejuvenation Conference last week in Germany, speaking about drug development strategies to improve health span. Read more about this important topic here:
0
0
4
Our CEO RJ Tesi was interviewed by @SullyOnTheAir about how #neuroinflammation causes #AlzheimersDisease (AD) and INmuneBio's approach to creating treatments. Watch the full interview here:
0
0
3
Today the FDA granted fully approval for the use of #lecanemab (#Leqembi) to 1 million+ Medicare patients in the early stages of #Alzheimers. Click the image to hear what our CEO has to say about the news.
0
0
6
A study published in @Nature suggests demyelination may be a part of the pathology of #AlzheimersDisease (AD). This could be a promising target to delay the development of AD. Read more:
0
1
5
@Alzheimersassoication published a new study that shows the drug development pipeline is advancing, but the need for efficient recruitment is vital. #ClinicalTrials . Read here:
0
0
4